ArticleJournal of neuropathology and experimental neurology2016
Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence.
Article in Journal of neuropathology and experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Clinical and molecular features of primary gliosarcoma with digital spatial whole-transcriptome analysis of glial and mesenchymal components.Brain pathology (Zurich, Switzerland) · 2026Article
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunology and cell biology · 2026Review
- Integrated biomarker mapping reveals differential expression of senescence profiles in IDH-wild-type glioblastoma recurrent versus primary tumors.Virchows Archiv : an international journal of pathology · 2026Article
- Microvessel density as a prognostic and predictive biomarker in newly diagnosed glioblastoma: correlations with radiological features and bevacizumab efficacy.Journal of neuro-oncology · 2025Article
- Immunotherapy for High-Grade Gliomas.Cancers · 2025Review
- Integrating Multiplex Immunohistochemistry and Machine Learning for Glioma Subtyping and Prognosis Prediction.MedComm · 2025Article
- Unravelling the mosaic: Epigenetic diversity in glioblastoma.Molecular oncology · 2024Review
- Cadherin Expression Profiles Define Glioblastoma Differentiation and Patient Prognosis.Cancers · 2024Article
- Review
- ELAVL2 loss promotes aggressive mesenchymal transition in glioblastoma.NPJ precision oncology · 2024Article
- Pyk2/FAK Signaling Is Upregulated in Recurrent Glioblastoma Tumors in a C57BL/6/GL261 Glioma Implantation Model.International journal of molecular sciences · 2023Article
- PotentFrontiers in oncology · 2023Article
- In-Depth Matrisome and Glycoproteomic Analysis of Human Brain Glioblastoma Versus Control Tissue.Molecular & cellular proteomics : MCP · 2022Article
- The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.Frontiers in immunology · 2022Article
- Cadherin Expression and EMT: A Focus on Gliomas.Biomedicines · 2021Review
- Perspective of mesenchymal transformation in glioblastoma.Acta neuropathologica communications · 2021Review
- Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma.Frontiers in oncology · 2021Article
- Immunohistochemically Characterized Intratumoral Heterogeneity Is a Prognostic Marker in Human Glioblastoma.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glioblastomas (GBM) are aggressive brain tumors that inevitably recur despite surgical resection, chemotherapy, and radiation. The degree to which recurrent GBM retains its initial immunophenotype is incompletely understood. We generated tissue microarrays of paired initial and posttreatment GBM (3 pairs positive and 17 negative for IDH1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.